Global Pretomanid Tablets Market Strategic Research Report

Scope of the Report

The global Pretomanid Tablets market size is predicted to grow from US$ 176 million in 2025 to US$ 394 million in 2032; it is expected to grow at a CAGR of 10.6% from 2026 to 2032.

Pretomanid tablets are a novel nitroimidazopyran anti-tuberculosis drug with potent bactericidal activity against multidrug-resistant tuberculosis. It exerts a bactericidal effect by inhibiting the synthesis of proteins and cell walls of Mycobacterium tuberculosis. As a core drug in the fully oral, long-course anti-tuberculosis regimen, it is often combined with bedaquiline and linezolid to form the BPaL regimen, for the treatment of extensively drug-resistant pulmonary tuberculosis or multidrug-resistant pulmonary tuberculosis with intolerance or ineffective conventional treatment. Featuring favorable oral absorption, strong tissue penetration and controllable safety, it is a core therapeutic drug for drug-resistant tuberculosis recommended by WHO, which significantly improves the cure rate of refractory tuberculosis.In 2025, global Pretomanid tablets production reached approximately 1,200,000 bottles

As an innovative drug in the global anti-tuberculosis field, Pretomanid tablets are strategically positioned and developed based on the clinical demand for drug-resistant tuberculosis and the construction of public health systems. As a core component of the fully oral, short-course BPaL (or BPaLM) combination regimen, Pretomanid is mainly indicated for multidrug-resistant and extensively drug-resistant tuberculosis. With superior efficacy and safety compared with traditional regimens, it has become a core drug recommended by the World Health Organization for drug-resistant tuberculosis, driving the global shift from long-course, high-adverse-effect tuberculosis treatments to short-course, high-compliance regimens.

In terms of market structure, the global market features a diversified supply pattern of innovator and generic drugs. The originator product developed by TB Alliance expands coverage in high-burden countries and low- and middle-income markets through multi-manufacturer authorization. Meanwhile, generic drugs qualified by WHO prequalification significantly improve drug accessibility via international public health procurement and regional supply chains, forming a supply system dominated by public health programs. In China, the approval and inclusion of Pretomanid in the medical insurance catalogue have substantially improved diagnosis and treatment accessibility and reduced patient burden, advancing domestic drug-resistant tuberculosis prevention and control into a new stage of highly effective and inclusive treatment.

The core drivers of market growth lie in three aspects: first, the persistent global incidence of drug-resistant tuberculosis sustains strong demand for new and effective treatment regimens; second, countries gradually incorporate BPaL-based short-course regimens into national tuberculosis programs, accelerating clinical adoption and policy implementation; third, price optimization and multi-manufacturer deployment balance drug value and healthcare system costs, expanding accessibility. Meanwhile, market development faces challenges such as regional disparities in medical resources, standardized management of treatment regimens, and improvement of drug resistance monitoring systems. Further consolidation of its core position in drug-resistant tuberculosis therapy relies on public health cooperation, improved cross-regional supply chains, and continuous accumulation of real-world data.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Pretomanid Tablets market?

What factors are driving Pretomanid Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Pretomanid Tablets market opportunities vary by end market size?

How does Pretomanid Tablets break out by Type, by Application?

This report presents a comprehensive overview of the global Pretomanid Tablets market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 26 tablets/box
• 182 tablets/bottle

Segment by Packaging

• Bottle
• Box

Segment by Storage

• Protect From Light
• Protect From Moisture

Segment by Production Technology

• Innovator
• Generic

Segment by Application

• Multidrug-Resistant Pulmonary Tuberculosis (MDR-TB)
• Extensively Drug-Resistant Pulmonary Tuberculosis (XDR-TB)
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Pretomanid Tablets market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Multidrug-Resistant Pulmonary Tuberculosis (MDR-TB), Extensively Drug-Resistant Pulmonary Tuberculosis (XDR-TB), Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact